+

US20020120012A1 - Methods of treating androgen deficiency in men using selective antiestrogens - Google Patents

Methods of treating androgen deficiency in men using selective antiestrogens Download PDF

Info

Publication number
US20020120012A1
US20020120012A1 US10/081,098 US8109802A US2002120012A1 US 20020120012 A1 US20020120012 A1 US 20020120012A1 US 8109802 A US8109802 A US 8109802A US 2002120012 A1 US2002120012 A1 US 2002120012A1
Authority
US
United States
Prior art keywords
men
selective
antiestrogen
treating
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
US10/081,098
Other versions
US7067557B2 (en
Inventor
Harry Fisch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Sciences Inc
Aspen Park Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/980,652 external-priority patent/US6391920B1/en
Application filed by Individual filed Critical Individual
Priority to US10/081,098 priority Critical patent/US7067557B2/en
Publication of US20020120012A1 publication Critical patent/US20020120012A1/en
Priority to PCT/US2002/037841 priority patent/WO2003072092A1/en
Priority to AU2002348245A priority patent/AU2002348245A1/en
Publication of US7067557B2 publication Critical patent/US7067557B2/en
Application granted granted Critical
Assigned to ASPEN PARK PHARMACEUTICALS, INC. reassignment ASPEN PARK PHARMACEUTICALS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: MILLENNIUM SCIENCES INC.
Assigned to MILLENNIUM SCIENCES INC. reassignment MILLENNIUM SCIENCES INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: FISCH, HARRY
Assigned to ASPEN PARK PHARMACEUTICALS, INC. reassignment ASPEN PARK PHARMACEUTICALS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: MILLENNIUM SCIENCES INC.
Assigned to BMO HARRIS BANK N.A. reassignment BMO HARRIS BANK N.A. SECURITY INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ASPEN PARK PHARMACEUTICALS, INC.
Assigned to ASPEN PARK PHARMACEUTICALS, INC. reassignment ASPEN PARK PHARMACEUTICALS, INC. RELEASE BY SECURED PARTY (SEE DOCUMENT FOR DETAILS). Assignors: BMO HARRIS BANK N.A.
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids

Definitions

  • the invention relates to the new use of antiestrogens for the production of a pharmaceutical agent for treating a relative androgen deficiency in men.
  • the hormonal environment of the sexual steroids is characterized by a significant preponderance of androgens over estrogens. While the circulating main component of androgens, testosterone, is detected in the serum in units in the range of nmol/l, the estrogen antagonist, estradiol, can be measured only in the range of pmol/l. This considerable preponderance of androgen can be detected basically in the entire late puberty period of life, but there is a clearly different intensity of this androgen dominance as a function of age. With increasing age and particularly so in those over the age of 60, there is a less pronounced emphasis of the androgen preponderance.
  • the relative testosterone deficiency per se can be regarded as responsible for a number of age-related disorders. Reduction of muscle mass accompanied by limitation of body performance capacity, reduction of bone density and in individual cases even osteoporosis, an increase in prostate size referred to as benign prostatic hyperplasia, reduction of libido and potency, and psycho-vegetative disorders such as depression and a decline in cognitive functions, which are disorders that are often generically referred to as Male Menopause and are caused by relative androgen deficiency in men. Libido is the desire to obtain an erection, while potency is the ability to have that erection.
  • the object of the present invention is to treat a relative androgen deficiency in older men and/or the specific disorders related to male menopause by the use of antiestrogens.
  • the disorders preferably comprise reduction of muscle mass, limitation of body performance capacity, reduction of bone density, reduction of libido, reduction of potency, reduction of benign prostatic hyperplasia, loss of cognitive function, insulin resistance, type 2 Diabetes, obesity, excessive weight, Alzheimer's disease, and combinations thereof.
  • the antiestrogens result in an endogenic rebalancing of the testosterone/estrogen ratio in men. As a result, the relative androgen deficiency is compensated for.
  • antiestrogens are all those compounds that compete with estrogen for estrogen-receptor-binding sites and may delay replenishment of intracellular estrogen receptors.
  • antiestrogens therefore, all such compounds are suitable, such as, for example, tamoxifen or a pharmaceutically acceptable salt thereof and clomiphene or a pharmaceutically acceptable salt thereof, for example:
  • tamoxifen citrate which is the trans-isomer of a triphenylethylene derivative.
  • the chemical name is (Z)2-[4-(1,2-diphenyl-1-butenyl) phenoxy]-N,N-dimethylethanamine 2-hydroxy-1,2,3-propanetricarboxylate (1:1) and sold under the trademark Novladex; and
  • clomiphene citrate which is 2[p-(2-chloro-1,2-diphenylvinyl) phenoxy]] trieth lamine citrate (1:1). It has the molecular formula of C26H28ClNO.C6H807 and a molecular weight of 598.09 and is sold under the trademark Clomid.
  • a pharmaceutically effective dosage of the antiestrogen is administered in older men for an effective time period, preferably, for 2 years and most preferably continuously. For example, at a daily dose of 5-10 mg once or twice a day, tamoxifen is administered to obtain a target range of mid-normal testosterone levels. A dose of 10-25 mg of clomid daily or every other day and up to 100 mg is administered to obtain the mid-normal levels. Measuring the serum concentration of testosterone and estradiol can thus give early indication of whether the desired hormone balance was achieved and optionally whether dose adjustment can be undertaken.
  • antiestrogen clomiphene citrate or tamoxifen citrate or a biologically equieffective amount of another antiestrogen is used daily or every other day to treat a relative androgen deficiency in men.
  • the antiestrogens can be administered, e.g., orally, parenterally or transdermally by a patch for example.
  • suitable means are especially tablets, coated tablets, capsules, pills, suspensions, or solutions that can be produced in a way that is commonly used and familiar to one skilled in the art, with the additives and vehicles that are commonly used for the formulation of antiestrogens that are to be administered orally.
  • the pharmaceutical agent that is produced according to the invention contains as an active ingredient per dosage unit of the antiestrogen at a daily or every other day dosage of 5 to 100 mg in addition to the commonly used additives, vehicles and/or diluents or other antiestrogens at biologically equieffective dosages.
  • each tablet contains 15.2 mg of tamoxifen citrate which is equivalent to 10 mg of tamoxifen.
  • each tablet contains 30.4 mg of tamoxifen citrate which is equivalent to 20 mg of tamoxifen.
  • the inactive ingredients are carboxymethylcellulose calcium, magnesium stearate, mannitol and starch.
  • Clomiphene citrate tablets is a mixture of two geometric isomers [cis (zuclomiphene) and trans (enclomiphene)]containing between 30% and 50% of the cisisomer.
  • a standard commercially available tablet contains 50 mg clomiphene citrate and the following inactive ingredients: corn starch, lactose, magnesium stearate, pregelatinized corn starch, and sucrose.
  • the current tablets are used primarily for treating female infertility. Treatment according to the present invention contemplates a redosing to accommodate the lower dosages specified herein.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The administration of antiestrogens to men suffering a relative androgen deficiency stimulates the body's production of testosterone leading to a correction of the deficiency. For example, male menopause, loss of cognitive function, insulin resistance, type 2 diabetes, obesity, excessive weight, Alzheimer's disease, and combinations thereof, can all be characterized by significant decreases in serum levels of bioavailable androgens. Administration of antiestrogens to men restores optimum serum levels of bioavailable androgens, and, thus, serves as a treatment for these disorders and relative androgen deficiency in general.

Description

  • This application is a continuation-in-part application of application Ser. No. 09/980,652 filed Oct. 26, 2001 which claims the priority of PCT/US01/15900 filed May 15, 2001 and which claims priority from application S.No. [0001] 60/207,496 filed May 26, 2000.
    • BACKGROUND OF THE INVENTION
  • The invention relates to the new use of antiestrogens for the production of a pharmaceutical agent for treating a relative androgen deficiency in men. [0002]
  • In men, increasing age leads to a reduction of testicular androgen production and androgen concentration in the organism. In contrast to the situation in women, in whom estrogen production drops to castration values within a comparatively short period, this takes decades in men and involves a gradual drop. The total concentration of testosterone in the serum in the older age group is significantly reduced compared to the values in young men. Because of the increase in steroid hormone-binding globulin (SHBG) that coincides with the aging process, moreover, the proportion of free, unbound, and thus biologically active testosterone drops. In addition, the serum levels of estrogens, although they are produced from androgens by direct conversion, do not drop in the same way as a function of age. As a result, the hormonal environment is significantly altered. [0003]
  • In men, the hormonal environment of the sexual steroids is characterized by a significant preponderance of androgens over estrogens. While the circulating main component of androgens, testosterone, is detected in the serum in units in the range of nmol/l, the estrogen antagonist, estradiol, can be measured only in the range of pmol/l. This considerable preponderance of androgen can be detected basically in the entire late puberty period of life, but there is a clearly different intensity of this androgen dominance as a function of age. With increasing age and particularly so in those over the age of 60, there is a less pronounced emphasis of the androgen preponderance. [0004]
  • In older men there are relative decreases in the preponderance of testosterone by 30-50% compared to the previous values found in young men. [0005]
  • The relative testosterone deficiency per se can be regarded as responsible for a number of age-related disorders. Reduction of muscle mass accompanied by limitation of body performance capacity, reduction of bone density and in individual cases even osteoporosis, an increase in prostate size referred to as benign prostatic hyperplasia, reduction of libido and potency, and psycho-vegetative disorders such as depression and a decline in cognitive functions, which are disorders that are often generically referred to as Male Menopause and are caused by relative androgen deficiency in men. Libido is the desire to obtain an erection, while potency is the ability to have that erection. [0006]
  • It is known that in younger men, testosterone values are also effectively increased by daily treatment with antiestrogens to treat male infertility. Treatment of Male Infertility, Springer-Verlag Berlin, Heidelberg, New York 1982; Fuse, H. et al., Archives of Andrology 31 (1993) 139-145); Nonsurgical Treatment of Male Infertility, Jarow, J., Infertility in the Male, pp. 410-422. However, it has been thought that antiestrogens do not seem well suited for treatment of a relative androgen deficiency in men. Thus, for example, U.S. Pat. No. 5,861,389 proposes the use of at least one aromatase inhibitor for the production of a pharmaceutical agent for treating a relative androgen deficiency in men. [0007]
  • With regard to changes in cognitive function in aging males, there is a relationship between declining levels of testosterone and Alzheimer's disease. Loss of testosterone with aging can result in mental status changes such as loss of cognitive function and can worsen symptoms of Alzheimer's disease. “Testosterone prevents the heat shock-induced overactivation of glycogen synthase kinase-3beta but not of cyclin-dependent kinase 5 and c-Jun NH2-terminal kinase and concomitantly abolishes hyperphosphorylation of tau Implications for Alzheimer's disease,” S. Papasozomenos and A. Shanava, Proc Natl Acad Sci U S A. Jan. 22, 2002. “Testosterone attenuates beta-amyloid toxicity in cultured hippocampal neurons,” C. Pike, Brain Res. Nov. 16, 2001; 919(1):160-5. “Testosterone reduces neuronal secretion of Alzheimer's beta-amyloid peptides,” Gouras et al, Proc Natl Acad Sci U S A. Feb. 1, 2000 vol. 97 no. 3 pp. 1202-5. [0008]
  • In older men, low testosterone levels is associated with obesity, upper body fat distribution and increased levels of glucose and insulin, and may worsen the symptoms and lead to the development of insulin resistance and type 2 Diabetes (Jee-Young Oh, Elizabeth Barrett-Connor, Nicole M. Wedick and Deborah L. Wingard, Endogenous Sex Hormones And The Development Of Type 2 Diabetes In Older Men And Women: The Rancho Bernardo Study, Diabetes Care, volume 25(1)55-60, January 2002.[0009]
    • SUMMARY OF THE INVENTION
  • The object of the present invention is to treat a relative androgen deficiency in older men and/or the specific disorders related to male menopause by the use of antiestrogens. The disorders preferably comprise reduction of muscle mass, limitation of body performance capacity, reduction of bone density, reduction of libido, reduction of potency, reduction of benign prostatic hyperplasia, loss of cognitive function, insulin resistance, type 2 Diabetes, obesity, excessive weight, Alzheimer's disease, and combinations thereof. [0010]
  • The use of antiestrogens in treating a relative androgen deficiency in older men results surprisingly in a long-term increase in the androgen level. [0011]
  • By gradually stimulating the body to produce testosterone, the antiestrogens result in an endogenic rebalancing of the testosterone/estrogen ratio in men. As a result, the relative androgen deficiency is compensated for. [0012]
  • For the purposes of this invention, antiestrogens are all those compounds that compete with estrogen for estrogen-receptor-binding sites and may delay replenishment of intracellular estrogen receptors. As antiestrogens, therefore, all such compounds are suitable, such as, for example, tamoxifen or a pharmaceutically acceptable salt thereof and clomiphene or a pharmaceutically acceptable salt thereof, for example: [0013]
  • tamoxifen citrate which is the trans-isomer of a triphenylethylene derivative. The chemical name is (Z)2-[4-(1,2-diphenyl-1-butenyl) phenoxy]-N,N-dimethylethanamine 2-hydroxy-1,2,3-propanetricarboxylate (1:1) and sold under the trademark Novladex; and [0014]
  • clomiphene citrate which is 2[p-(2-chloro-1,2-diphenylvinyl) phenoxy]] trieth lamine citrate (1:1). It has the molecular formula of C26H28ClNO.C6H807 and a molecular weight of 598.09 and is sold under the trademark Clomid. [0015]
  • The list of antiestrogens above is not exhaustive, other compounds that meet the set requirements, are also considered. [0016]
  • A pharmaceutically effective dosage of the antiestrogen is administered in older men for an effective time period, preferably, for 2 years and most preferably continuously. For example, at a daily dose of 5-10 mg once or twice a day, tamoxifen is administered to obtain a target range of mid-normal testosterone levels. A dose of 10-25 mg of clomid daily or every other day and up to 100 mg is administered to obtain the mid-normal levels. Measuring the serum concentration of testosterone and estradiol can thus give early indication of whether the desired hormone balance was achieved and optionally whether dose adjustment can be undertaken. [0017]
  • In general, 5 to 1000 mg, preferably 10 to 100 mg, of antiestrogen clomiphene citrate or tamoxifen citrate or a biologically equieffective amount of another antiestrogen is used daily or every other day to treat a relative androgen deficiency in men. [0018]
  • The antiestrogens can be administered, e.g., orally, parenterally or transdermally by a patch for example. [0019]
  • For the preferred oral administration, suitable means are especially tablets, coated tablets, capsules, pills, suspensions, or solutions that can be produced in a way that is commonly used and familiar to one skilled in the art, with the additives and vehicles that are commonly used for the formulation of antiestrogens that are to be administered orally. [0020]
  • The pharmaceutical agent that is produced according to the invention contains as an active ingredient per dosage unit of the antiestrogen at a daily or every other day dosage of 5 to 100 mg in addition to the commonly used additives, vehicles and/or diluents or other antiestrogens at biologically equieffective dosages. [0021]
  • When antiestrogens are used for treating male menopause, the estrogen concentration is effectively lowered. The easy controllability of the treatment distinguishes treatment with an antiestrogen. For 10 mg tablets, each tablet contains 15.2 mg of tamoxifen citrate which is equivalent to 10 mg of tamoxifen. For 20 mg tablets, each tablet contains 30.4 mg of tamoxifen citrate which is equivalent to 20 mg of tamoxifen. The inactive ingredients are carboxymethylcellulose calcium, magnesium stearate, mannitol and starch. [0022]
  • Clomiphene citrate tablets is a mixture of two geometric isomers [cis (zuclomiphene) and trans (enclomiphene)]containing between 30% and 50% of the cisisomer. A standard commercially available tablet contains 50 mg clomiphene citrate and the following inactive ingredients: corn starch, lactose, magnesium stearate, pregelatinized corn starch, and sucrose. The current tablets are used primarily for treating female infertility. Treatment according to the present invention contemplates a redosing to accommodate the lower dosages specified herein. [0023]
  • It is also contemplated that combinations of antiestrogens can be administered or that combinations of antiestrogens and other testosterone producing drugs can be used. [0024]

Claims (22)

What is claimed is:
1. A method for treating a decline in cognitive function related to male menopause in men comprising administering a selective antiestrogen.
2. A method for treating Alzheimer's disease related to male menopause in men comprising administering a selective antiestrogen.
3. A method for treating insulin resistance related to male menopause in men comprising administering a selective antiestrogen.
4. A method for treating weight gain related to male menopause comprising administering a selective antiestrogen.
5. A method for treating type 2 diabetes related to male menopause comprising administering a selective antiestrogen.
6. The method according to claim 1, 2, 3, 4, or 5, wherein the selective antiestrogen is tamoxifen.
7. The method according to claim 1, 2, 3, 4, or 5, wherein the selective antiestrogen is tamoxifen citrate.
8. The method according to claim 1, 2, 3, 4, or 5, wherein the selective antiestrogen is clomiphine.
9. The method according to claim 1, 2, 3, 4, or 5, wherein the selective antiestrogen is clomiphine citrate.
10. The method according to claim 9, wherein the clomiphine citrate comprises the cis isomer.
11. The method according to claim 9, wherein the clomiphine citrate comprises the trans isomer.
12. A method of treating Alzheimer's disease, comprising administering a selective antiestrogen.
13. A method of treating insulin resistance, comprising administering a selective antiestrogen.
14. A method of treating type 2 diabetes, comprising administering a selective antiestrogen.
15. A method of treating a decline in cognitive function, comprising administering a selective antiestrogen.
16. A method of treating weight gain, comprising administering a selective antiestrogen.
17. The method according to claim 12, 13, 14, 15, or 16, wherein the selective antiestrogen is tamoxifen.
18. The method according to claim 12, 13, 14, 15, or 16, wherein the selective antiestrogen is tamoxifen citrate.
19. The method according to claim 12, 13, 14, 15, or 16, wherein the selective antiestrogen is clomiphine.
20. The method according to claim 12, 13, 14, 15, or 16, wherein the selective antiestrogen is clomiphine citrate.
21. The method according to claim 20, wherein the clomiphine citrate comprises the cis isomer.
22. The method according to claim 20, wherein the clomiphine citrate comprises the trans isomer.
US10/081,098 2000-05-26 2002-02-21 Methods of treating androgen deficiency in men using selective antiestrogens Expired - Lifetime US7067557B2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US10/081,098 US7067557B2 (en) 2000-05-26 2002-02-21 Methods of treating androgen deficiency in men using selective antiestrogens
PCT/US2002/037841 WO2003072092A1 (en) 2002-02-21 2002-11-25 Methods of treating androgen deficiency in men using selective antiestrogens
AU2002348245A AU2002348245A1 (en) 2002-02-21 2002-11-25 Methods of treating androgen deficiency in men using selective antiestrogens

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US20749600P 2000-05-26 2000-05-26
US09/980,652 US6391920B1 (en) 2000-05-26 2001-05-15 Methods of treating androgen deficiency in men using selective antiestrogens
PCT/US2001/015900 WO2001091744A1 (en) 2000-05-26 2001-05-15 Methods of treating androgen deficiency in men using selective antiestrogens
USPCT/US01/15900 2001-05-15
US10/081,098 US7067557B2 (en) 2000-05-26 2002-02-21 Methods of treating androgen deficiency in men using selective antiestrogens

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09/980,652 Continuation-In-Part US6391920B1 (en) 2000-05-26 2001-05-15 Methods of treating androgen deficiency in men using selective antiestrogens

Publications (2)

Publication Number Publication Date
US20020120012A1 true US20020120012A1 (en) 2002-08-29
US7067557B2 US7067557B2 (en) 2006-06-27

Family

ID=27765251

Family Applications (1)

Application Number Title Priority Date Filing Date
US10/081,098 Expired - Lifetime US7067557B2 (en) 2000-05-26 2002-02-21 Methods of treating androgen deficiency in men using selective antiestrogens

Country Status (3)

Country Link
US (1) US7067557B2 (en)
AU (1) AU2002348245A1 (en)
WO (1) WO2003072092A1 (en)

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003005954A3 (en) * 2001-07-09 2003-10-23 Zonagen Inc Methods and materials for the treatment of testosterone deficiency in men
US20040171697A1 (en) * 2001-07-09 2004-09-02 Zonagen, Inc. Methods and compositions with trans-clomiphene for treating wasting and lipodystrophy
US20040214898A1 (en) * 2001-11-29 2004-10-28 Steiner Mitchell S. Methods for treating hot flashes
US20050080143A1 (en) * 2001-11-29 2005-04-14 Steiner Mitchell S. Treatment of androgen-deprivation induced osteoporosis
US20050220831A1 (en) * 2003-02-27 2005-10-06 Novasel Australia Pty Ltd Poloxamer emulsion preparations
WO2006019916A1 (en) * 2004-07-14 2006-02-23 Repros Therapeutics Inc. Trans-clomiphene for the treatment of benign prostate hypertrophy, prostate cancer, hypogonadism, elevated triglycerides and high cholesterol
US20060269611A1 (en) * 2001-11-29 2006-11-30 Steiner Mitchell S Prevention and treatment of androgen-deprivation induced osteoporosis
US20070197664A1 (en) * 2001-11-29 2007-08-23 Steiner Mitchell S Prevention and treatment of androgen-deprivation induced osteoporosis
US20070249726A1 (en) * 2001-07-09 2007-10-25 Podolski Joseph S Methods and compositions with trans-clomiphene
US20080249183A1 (en) * 2001-11-29 2008-10-09 Steiner Mitchell S Treatment of androgen-deprivation induced osteoporosis
WO2009039344A1 (en) * 2007-09-21 2009-03-26 Harry Fisch Treatment of migraine headaches using antiestrogens
US20090215906A1 (en) * 2005-02-04 2009-08-27 Repros Therapeutics Inc. Methods and materials with trans-clomiphene for the treatment of male infertility
US20090215907A1 (en) * 2005-03-22 2009-08-27 Podolski Joseph S Dosing regimes for trans-clomiphene
EP2211848A1 (en) * 2007-10-16 2010-08-04 Repros Therapeutics Inc. Trans-clomiphene for metabolic syndrome
US20160051498A1 (en) * 2014-08-20 2016-02-25 Professional Compounding Centers Of America (Pcca) Transdermal Pharmaceutical Compositions Including Testosterone and a C-SERM
US9687458B2 (en) 2012-11-02 2017-06-27 Repros Therapeutics Inc. Trans-clomiphene for use in cancer therapy
US9981906B2 (en) 2011-08-04 2018-05-29 Repros Therapeutics Inc. Trans-clomiphene metabolites and uses thereof

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005105063A1 (en) * 2004-05-03 2005-11-10 Universita' Degli Studi Di Firenze Pharmaceutical compositions containing serms for the treatment of alzheimer's disease
JP2008511615A (en) * 2004-09-03 2008-04-17 ホルモス メディカル リミテッド Estrogen receptor selective modulator for use in the manufacture of a pharmaceutical preparation for use in the treatment or prevention of androgen deficiency
US20110118355A1 (en) * 2007-09-21 2011-05-19 Harry Fisch Treatment of migraine headaches using antiestrogens
US20130165524A1 (en) * 2007-10-16 2013-06-27 Repros Therapeutics Inc. Trans-clomiphene for metabolic syndrome
US20090215733A1 (en) * 2008-02-26 2009-08-27 Michael Charles Scally Therapy for the prophylaxis or treatment of adverse body composition changes and/or decreased muscle strength after androgen or gnrh analogue intake
TW201500041A (en) * 2008-11-07 2015-01-01 Repros Therapeutics Inc Trans-clomiphene for metabolic syndrome and diabetes mellitus type 2
US9744177B2 (en) 2014-03-10 2017-08-29 Endorecherche, Inc. Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5728688A (en) * 1993-01-19 1998-03-17 Endoreoherche, Inc. Therapeutic methods and delivery systems utilizing sex steroid precursors
US5861389A (en) * 1994-09-22 1999-01-19 Schering Aktiengesellschaft Methods of treating androgen deficiency in men using selective aromatase inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2030174C (en) * 1990-01-10 1996-12-24 Anthony H. Cincotta Process for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hypoglycemia in vertebrates
GB2244431A (en) * 1990-05-31 1991-12-04 Farmos Oy Treatment of age related memory impairment and other cognitive disorders
WO2001091744A1 (en) * 2000-05-26 2001-12-06 Harry Fisch Methods of treating androgen deficiency in men using selective antiestrogens

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5728688A (en) * 1993-01-19 1998-03-17 Endoreoherche, Inc. Therapeutic methods and delivery systems utilizing sex steroid precursors
US5861389A (en) * 1994-09-22 1999-01-19 Schering Aktiengesellschaft Methods of treating androgen deficiency in men using selective aromatase inhibitors

Cited By (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7368480B2 (en) 2001-07-09 2008-05-06 Repros Therapeutics Inc. Methods and compositions with trans-clomiphene
US20040097597A1 (en) * 2001-07-09 2004-05-20 Zonagen, Inc. Methods and compositions with trans-clomiphene
US20040171697A1 (en) * 2001-07-09 2004-09-02 Zonagen, Inc. Methods and compositions with trans-clomiphene for treating wasting and lipodystrophy
US10561624B2 (en) 2001-07-09 2020-02-18 Repros Therapeutics Inc. Methods and materials for the treatment of testosterone deficiency in men
US20040241224A1 (en) * 2001-07-09 2004-12-02 Podolski Joseph S Methods and materials for the treatment of testosterone deficiency in men
US8618176B2 (en) 2001-07-09 2013-12-31 Repros Therapeutics Inc. Methods and materials for the treatment of testosterone deficiency in men
US20100286281A1 (en) * 2001-07-09 2010-11-11 Repros Therapeutics Inc. Methods and materials for the treatment of testosterone deficiency in men
US7759360B2 (en) 2001-07-09 2010-07-20 Repros Therapeutics Inc. Methods and materials for the treatment of testosterone deficiency in men
US7737185B2 (en) 2001-07-09 2010-06-15 Repros Therapeutics Inc. Methods and compositions with trans-clomiphene
US7173064B2 (en) 2001-07-09 2007-02-06 Repros Therapeutics Inc. Methods and compositions with trans-clomiphene for treating wasting and lipodystrophy
WO2003005954A3 (en) * 2001-07-09 2003-10-23 Zonagen Inc Methods and materials for the treatment of testosterone deficiency in men
US20070249726A1 (en) * 2001-07-09 2007-10-25 Podolski Joseph S Methods and compositions with trans-clomiphene
US20080249183A1 (en) * 2001-11-29 2008-10-09 Steiner Mitchell S Treatment of androgen-deprivation induced osteoporosis
US20060269611A1 (en) * 2001-11-29 2006-11-30 Steiner Mitchell S Prevention and treatment of androgen-deprivation induced osteoporosis
US20070197664A1 (en) * 2001-11-29 2007-08-23 Steiner Mitchell S Prevention and treatment of androgen-deprivation induced osteoporosis
US20040214898A1 (en) * 2001-11-29 2004-10-28 Steiner Mitchell S. Methods for treating hot flashes
US20050080143A1 (en) * 2001-11-29 2005-04-14 Steiner Mitchell S. Treatment of androgen-deprivation induced osteoporosis
US20050220831A1 (en) * 2003-02-27 2005-10-06 Novasel Australia Pty Ltd Poloxamer emulsion preparations
WO2006019916A1 (en) * 2004-07-14 2006-02-23 Repros Therapeutics Inc. Trans-clomiphene for the treatment of benign prostate hypertrophy, prostate cancer, hypogonadism, elevated triglycerides and high cholesterol
US20080242726A1 (en) * 2004-07-14 2008-10-02 Podolski Joseph S Trans-Clomiphene for the Treatment of Benign Prostate Hypertrophy, Porstate Cancer, Hypogonadism Elevated Triglycerides and High Cholesterol
US20090215906A1 (en) * 2005-02-04 2009-08-27 Repros Therapeutics Inc. Methods and materials with trans-clomiphene for the treatment of male infertility
US20090215907A1 (en) * 2005-03-22 2009-08-27 Podolski Joseph S Dosing regimes for trans-clomiphene
US8247456B2 (en) 2005-03-22 2012-08-21 Repros Therapeutics Inc. Dosing regimes for trans-clomiphene
WO2009039344A1 (en) * 2007-09-21 2009-03-26 Harry Fisch Treatment of migraine headaches using antiestrogens
US8377991B2 (en) 2007-10-16 2013-02-19 Repros Therapeutics Inc. Trans-clomiphene for metabolic syndrome
US8372887B2 (en) 2007-10-16 2013-02-12 Repros Therapeutics Inc. Trans-clomiphene for metabolic syndrome
EP2826475A1 (en) * 2007-10-16 2015-01-21 Repros Therapeutics Inc. Trans-clomiphene for treating diabetes in hypogonadal men
EP2211848A1 (en) * 2007-10-16 2010-08-04 Repros Therapeutics Inc. Trans-clomiphene for metabolic syndrome
US9981906B2 (en) 2011-08-04 2018-05-29 Repros Therapeutics Inc. Trans-clomiphene metabolites and uses thereof
US9687458B2 (en) 2012-11-02 2017-06-27 Repros Therapeutics Inc. Trans-clomiphene for use in cancer therapy
US20160051498A1 (en) * 2014-08-20 2016-02-25 Professional Compounding Centers Of America (Pcca) Transdermal Pharmaceutical Compositions Including Testosterone and a C-SERM

Also Published As

Publication number Publication date
WO2003072092A1 (en) 2003-09-04
AU2002348245A1 (en) 2003-09-09
US7067557B2 (en) 2006-06-27

Similar Documents

Publication Publication Date Title
US7067557B2 (en) Methods of treating androgen deficiency in men using selective antiestrogens
US6391920B1 (en) Methods of treating androgen deficiency in men using selective antiestrogens
AU2001261684A1 (en) Methods of treating androgen deficiency in men using selective antiestrogens
US6884795B2 (en) Pharmaceutical compositions and uses for androst-5-ene-3β, 17β-diol
EP1322336B1 (en) Method of increasing testosterone and related steroid concentrations in women
JP6270281B2 (en) Dosing regimen for trans-clomiphene
JPH0680017B2 (en) Process for producing composition comprising anti-estrogen and carrier
HU214598B (en) Procedure for the Preparation of Contraceptives and Hormone Therapy for the Formulations Containing Estrogen and Progestine
CN1395488A (en) Drospirenone for hormone replacement therapy
JP4845165B2 (en) Methods and substances for the treatment of testosterone deficiency in men
US20030191096A1 (en) Method of hormonal therapy
PL192979B1 (en) Hormonal preparation consisting of an oestrogen compound and of a progesterone compound
TW201031400A (en) Trans-clomiphene for metabolic syndrome and diabetes mellitus type 2
US20090023693A1 (en) New drospirenone/17beta-estradiol regimen, pharmaceutical combination product and kit for performing this regimen
JP2008530016A (en) Methods using trans-clomiphene for the treatment of male infertility and substances containing trans-clomiphene
JP6967012B2 (en) Steroid hormones for treating and preventing waveburst arrhythmias
WO2017147264A1 (en) Oral dosage form of both clomiphene isomers and method of using same to treat secondary hypogonadism
HK1084018A (en) Estrogen replacement regimen
HK1024420A (en) Hormonal composition consisting of an oestrogen compound and of a progestational compound

Legal Events

Date Code Title Description
STCF Information on status: patent grant

Free format text: PATENTED CASE

REMI Maintenance fee reminder mailed
FPAY Fee payment

Year of fee payment: 4

SULP Surcharge for late payment
FPAY Fee payment

Year of fee payment: 8

AS Assignment

Owner name: ASPEN PARK PHARMACEUTICALS, INC., NEW YORK

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MILLENNIUM SCIENCES INC.;REEL/FRAME:040120/0087

Effective date: 20141124

Owner name: MILLENNIUM SCIENCES INC., NEW YORK

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:FISCH, HARRY;REEL/FRAME:040477/0461

Effective date: 20141124

AS Assignment

Owner name: ASPEN PARK PHARMACEUTICALS, INC., NEW YORK

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MILLENNIUM SCIENCES INC.;REEL/FRAME:040290/0647

Effective date: 20141124

AS Assignment

Owner name: BMO HARRIS BANK N.A., ILLINOIS

Free format text: SECURITY INTEREST;ASSIGNOR:ASPEN PARK PHARMACEUTICALS, INC.;REEL/FRAME:040597/0731

Effective date: 20161128

FEPP Fee payment procedure

Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.)

AS Assignment

Owner name: ASPEN PARK PHARMACEUTICALS, INC., FLORIDA

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:BMO HARRIS BANK N.A.;REEL/FRAME:045090/0402

Effective date: 20180206

FEPP Fee payment procedure

Free format text: 11.5 YR SURCHARGE- LATE PMT W/IN 6 MO, SMALL ENTITY (ORIGINAL EVENT CODE: M2556)

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 12TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2553)

Year of fee payment: 12

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载